PFO
MDCO

Pathstone Family Office’s Medicines Co MDCO Stock Holding History

Pathstone Family Office’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85
Closed -$2K – 981
2019
Q1 		$2K Hold
85
– – ﹤0.01% 826
2018
Q4 		$2K Buy
+85
New +$1.98K ﹤0.01% 496

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Pathstone Family Office's MDCO Position: Q2 2019 in Review

Pathstone Family Office sold out of Medicines Co (MDCO) in Q2 2019, closing a stake of 85 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in MDCO in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 228 funds tracked by Wall St. Rank hold MDCO as of Q2 2019.

  • Pathstone Family Office reported no remaining Medicines Co position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 85 Medicines Co shares in Q2 2019, an estimated $2K.
  • Pathstone Family Office first reported a position in Medicines Co in Q4 2018 and held it in 2 quarters.
  • Pathstone Family Office's Medicines Co position peaked at $2K in Q1 2019.
  • 228 funds tracked by Wall St. Rank held Medicines Co as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.